UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000049842
Receipt number R000056770
Scientific Title An evaluation study of the improving effects of intake of ONO-SR/AST-SOYPC on cognitive function: a randomized, placebo-controlled, double-blind, parallel-group comparison study
Date of disclosure of the study information 2024/07/21
Last modified on 2024/04/16 09:17:16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study to improve cognitive function by the ONO-SR/AST-SOYPC intake

Acronym

A study to improve cognitive function by the ONO-SR/AST-SOYPC intake

Scientific Title

An evaluation study of the improving effects of intake of ONO-SR/AST-SOYPC on cognitive function: a randomized, placebo-controlled, double-blind, parallel-group comparison study

Scientific Title:Acronym

A study to improve cognitive function by the ONO-SR/AST-SOYPC intake

Region

Japan


Condition

Condition

Healthy Japanese adults

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aims to confirm the effects of consuming this test food on cognitive function and quality of life (QOL) in men or women aged between 50 and 80, and noticed a cognitive function decline

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

1. The standardized score of composite memory at 12 weeks after consumption (12w)

Key secondary outcomes

1. The standardized scores of cognitive function tests (except for composite memory) at 12w

2. The Profile of Mood States 2nd Edition (POMS2) at 12w

3. Plasma cortisol at 12w


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation


Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Duration: 12 weeks
Test food: ONO-SR/AST-SOYPC (containing salmon roe oil, astaxanthin and soy lecithin)
Administration: Take four capsules with water without chewing after meals


Interventions/Control_2

Duration: 12 weeks
Test food: Capsule not containing salmon roe oil
Administration: Take four capsules with water without chewing after meals


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Japanese

2. Men or women

3. Men or women aged between 50 and 80

4. Healthy subjects

5. Subjects whose scoring of Mini Mental State Examination (MMSE) is between 24 and 28

6. Subjects who have relatively low standardized score in composite memory measured using Cognitrax

7. Subjects having a "yes" in the validity indicator of Cognitrax on both verbal memory and visual memory

8. Subjects who are judged as eligible to participate in the study by the physician

Key exclusion criteria

Subjects who
1.have a pacemaker or an implantable cardioverter defibrillator
2.have COVID-19
3.have a past medical history (PMH) of malignant tumor, heart failure, and myocardial infarction
4.are undergoing treatment for chronic diseases (e.g. atrial fibrillation, arrhythmia, hepatopathy, nephropathy, cerebrovascular disorder, rheumatism, diabetes, dyslipidemia, hypertension, gastrointestinal disorder)
5.have a PMH or current medical history (CMH) of psychosis, dementia, cranial nerve diseases, or cerebrovascular diseases
6.have depressive symptoms/have been diagnosed with depression
7.usually take medicines, herbal medicines, and supplements (Foods for Specified Health Uses, or Foods with Functional Claims)
8.take health foods with rich e.g. DHA, EPA or blue-backed fish (e.g. sardines, mackerel, and saury) at least 4 times a week
9.consecutively take medicines or health foods that may influence the results (e.g. ginkgo leaf extract, tocotrienol, astaxanthin, GABA, phosphatidylserine, and plasmalogen) at least a week
10.have difficulty performing cognitive tests due to poor eyesight or hearing
11.have a CMH of menopausal symptoms
12.have a PMH or CMH of drug or alcohol dependence
13.will have an irregular life due to e.g. night shifts twice or more during this trial
14.are smokers/have quit smoking within 12 months before the pre-consumption assessment (0w)
15.donated 200 or 400 mL of whole blood/had a blood transfusion within 3 months before 0w
16.are judged as ineligible to participate from laboratory values or measurement at 0w
17.are judged as ineligible to participate from lifestyle questionnaires
18.are allergic to medicines or test food related products
19.have a PMH of atopic dermatitis
20.are pregnant/lactating/will be pregnant during this trial
21.have been enrolled in other clinical trials within 28 days before agreeing to participate or plan to participate another trial during this trial
22.are judged as ineligible to participate by the physician

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Tsuyoshi
Middle name
Last name Takara

Organization

Medical Corporation Seishinkai, Takara Clinic

Division name

Director

Zip code

141-0022

Address

9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan

TEL

03-5793-3623

Email

t-takara@takara-clinic.com


Public contact

Name of contact person

1st name Naoko
Middle name
Last name Suzuki

Organization

ORTHOMEDICO Inc.

Division name

R&D Department

Zip code

112-0002

Address

2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.

TEL

03-3818-0610

Homepage URL


Email

nao@orthomedico.jp


Sponsor or person

Institute

ORTHOMEDICO Inc.

Institute

Department

Personal name



Funding Source

Organization

ONO PHARMACEUTICAL CO.,LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Medical Corporation Seishinkai, Takara Clinic

Nerima Medical Association, Minami-machi Clinic

Name of secondary funder(s)



IRB Contact (For public release)

Organization

the ethical committee of the Takara Clinic, Medical Corporation Seishinkai

Address

9F Taisei Building, 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan.

Tel

03-5793-3623

Email

IRB@takara-clinic.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)

南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)


Other administrative information

Date of disclosure of the study information

2024 Year 07 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

110

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2022 Year 11 Month 16 Day

Date of IRB

2022 Year 11 Month 16 Day

Anticipated trial start date

2022 Year 12 Month 20 Day

Last follow-up date

2023 Year 07 Month 22 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 12 Month 20 Day

Last modified on

2024 Year 04 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056770


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name